ADVM Adverum Biotechnologies Inc.

11.45
-0.19  -2%
Previous Close 11.64
Open 11.66
Price To Book 4.51
Market Cap 739,533,127
Shares 64,588,046
Volume 673,531
Short Ratio
Av. Daily Volume 1,138,348
Stock charts supplied by TradingView

NewsSee all news

  1. Adverum Biotechnologies Reports Continued Momentum with OPTIC Trial for ADVM-022 Intravitreal Gene Therapy in Wet AMD and Provides 2020 Outlook

    -- OPTIC phase 1 trial progressing with plans to complete patient dosing in cohort three, begin enrollment in cohort four in 1Q20 -- -- IND application planned for ADVM-022 in diabetic retinopathy in 1H20; Patient

  2. Adverum Biotechnologies Reports Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at the Atlantic Coast Retina Club Macula 20/20 Annual Meeting

    --44 week median follow up for patients (n=6)----Zero anti-VEGF rescue injections required following intravitreal ADVM-022; First patient has reached 52-weeks post treatment----Vision remains stable and anatomical

  3. Adverum Biotechnologies to Present at Upcoming Conferences

    MENLO PARK, Calif., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the

  4. Adverum Biotechnologies to Participate in Piper Jaffray's 31st Annual Healthcare Conference

    MENLO PARK, Calif., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that

  5. Adverum Biotechnologies Reports Recent Business Progress and Third Quarter 2019 Financial Results

    -- OPTIC phase 1 trial in wet AMD progressing well with dosing of third cohort underway-- -- Company to host conference call today at 1:30 pm PT / 4:30 pm ET -- MENLO PARK, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) --

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Development to be discontinued - noted November 1, 2018.
ADVM-043
Alpha-1 Antitrypsin (A1AT) Deficiency
Phase 2a negative data released June 2015 (met primary endpoint but increase in retinal thickness). As a result Phase 2b development will not proceed.
AVA-101
Wet age-related macular degeneration (Wet-AMD)
Cohort 1 long-term data and Cohort 2 24-week data due February 8, 2020 at the Angiogenesis, Exudation, and Degeneration 2020 symposium.
ADVM-022
Wet age-related macular degeneration (Wet-AMD)

Latest News

  1. Adverum Biotechnologies Reports Continued Momentum with OPTIC Trial for ADVM-022 Intravitreal Gene Therapy in Wet AMD and Provides 2020 Outlook

    -- OPTIC phase 1 trial progressing with plans to complete patient dosing in cohort three, begin enrollment in cohort four in 1Q20 -- -- IND application planned for ADVM-022 in diabetic retinopathy in 1H20; Patient

  2. Adverum Biotechnologies Reports Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at the Atlantic Coast Retina Club Macula 20/20 Annual Meeting

    --44 week median follow up for patients (n=6)----Zero anti-VEGF rescue injections required following intravitreal ADVM-022; First patient has reached 52-weeks post treatment----Vision remains stable and anatomical

  3. Adverum Biotechnologies to Present at Upcoming Conferences

    MENLO PARK, Calif., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the

  4. Adverum Biotechnologies to Participate in Piper Jaffray's 31st Annual Healthcare Conference

    MENLO PARK, Calif., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that

  5. Adverum Biotechnologies Reports Recent Business Progress and Third Quarter 2019 Financial Results

    -- OPTIC phase 1 trial in wet AMD progressing well with dosing of third cohort underway-- -- Company to host conference call today at 1:30 pm PT / 4:30 pm ET -- MENLO PARK, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) --

  6. Adverum Biotechnologies to Host a Conference Call and Webcast to Report Third Quarter 2019 Financial Results and Provide Corporate Updates

    MENLO PARK, Calif., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced today

  7. Adverum Biotechnologies Expands Leadership Team with the Appointment of Peter Soparkar as Chief Legal Officer

    MENLO PARK, Calif., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the

  8. Adverum Biotechnologies Reports Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting

    -- Zero anti-VEGF rescue injections required in the first cohort and durable efficacy with median follow up of 34 weeks ---- Sequential enrollment planned for OPTIC third and fourth cohorts ---- Company to host and

  9. Adverum Biotechnologies to Present Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy to Treat Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting

    MENLO PARK, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced it

  10. Adverum Biotechnologies Reports Positive 24-Week Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy to Treat Wet AMD

    -- Zero anti-VEGF rescue injections required after one-time intravitreal dose of ADVM-022 -- -- Sustained improvements in retinal anatomy -- -- Was safe and well tolerated --  -- Data being presented during podium

  11. Adverum Biotechnologies to Host a Conference Call and Webcast to Present 24-week Data from First Cohort of OPTIC Trial of ADVM-022 Intravitreal Injection Gene Therapy to Treat Wet AMD at Retina Society 2019 Annual Meeting

    -- Podium presentation of 24-week data from first cohort of the OPTIC trial at Retina Society 2019 Annual Meeting on September 12, 2019 at 7:41 am BST -- -- Adverum to host a conference call and webcast to review

  12. Adverum Biotechnologies to Present 24-Week Data from First Cohort of OPTIC Trial of ADVM-022 Intravitreal Injection Gene Therapy to Treat Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting in October

    MENLO PARK, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that

  13. Adverum Biotechnologies to Present 24-Week Data from First Cohort of OPTIC Trial of ADVM-022 Intravitreal Injection Gene Therapy to Treat Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting in October

    MENLO PARK, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that